|
|
|
|
||
Re: Early dataI have been out of this stock for a while, but the latest ARO-HBV results piqued my interest somewhat. I am trying to assess if this result is better than those of ARC520/521. A few observations: 1) The 100 mg results looks good - 2.0 log average and 4.0 log max. But the result is somewhat skewed by the exceptional result of a single patient. Simple algebra shows that the average KD of the other 3 is 1.33 log or 95.4 %. 2) The 200 mg data at 71 days is about the same as the 100 mg data. It is likely that the KD at 85 days will be less than the 2 log KD of 100 mg because it probably does not have the single exceptional result to help the average. 3) NADIR has not been reached 4) The latest ARC520 multi-dose results showed : HBeAg pos - 3.41 log average and 5.31 log Max HBeAg neg - 1.4 log average and 1.46 Max I agree that we cannot draw much conclusion at this time. ARO-HBV is lmost ikely to be better for HBeAg neg patients but it is to be expected. We need more info for better assessment. |
return to message board, top of board |